IL17A and myeloid sarcoma: Both Th1 (IFNγ and IL-12p70) and Th17 (IL-17, IL-21, IL-23, and IL-1β) proinflammatory cytokines were significantly suppressed at all long-term timepoints (6, 12, and 24 months) examined in MS patients when compared to baseline (Figure 2A).